GlassScriptPhysician profile
Donald M Habbe
NPI 1538160338
$266.12
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Anatomic Pathology & Clinical Pathology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $104.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $60.16 | 2019-2020 | |
| Janssen Biotech, INC. | $28.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.31 | 2019-2020 | |
| Puma Biotechnology, INC. | $20.31 | 2020 | |
| Amgen INC. | $19.86 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2019 | |
| Merck Sharp & Dohme LLC | $15.62 | 2019 | |
| Seagen INC. | $15.15 | 2020 | |
| Celgene Corporation | $14.36 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.05 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.53 | 2019 | |
| Kyowa Kirin, INC. | $11.41 | 2020 | |
| Tesaro, INC. | $10.93 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Habbe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.